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Abstract
Deletion and duplication of 16p11.2 (BP4–BP5) have been associated with an increased risk of intellectual disability and
psychiatric disorder. This is the ﬁrst study to compare the frequency of a broad spectrum of psychiatric disorders in
children with 16p11.2 deletion and duplication. We aimed to evaluate (1) the nature and prevalence of
psychopathology associated with copy number variation (CNV) in children with 16p11.2 by comparing deletion and
duplication carriers with family controls; (2) whether deletion and duplication carriers differ in frequency of
psychopathology. 217 deletion carriers, 77 deletion family controls, 114 duplication carriers, and 32 duplication family
controls participated in the study. Measures included standardized research diagnostic instruments. Deletion carriers
had a higher frequency of any psychiatric disorder (OR= 8.9, p < 0.001), attention deﬁcit hyperactivity disorder (ADHD)
(OR= 4.0, p= 0.01), and autism spectrum disorder (ASD) (OR= 39.9, p= 0.01) than controls. Duplication carriers had a
higher frequency of any psychiatric diagnosis (OR= 5.3, p= 0.01) and ADHD (OR= 7.0, p= 0.02) than controls. The
prevalence of ASD in child carriers of deletions and duplications was similar (22% versus 26%). Comparison of the two
CNV groups indicated a higher frequency of ADHD in children with the duplication than deletion (OR= 2.7, p= 0.04)
as well as a higher frequency of overall psychiatric disorders (OR= 2.8, p= 0.02) and psychotic symptoms (OR= 4.7, p
= 0.02). However, no differences between deletion and duplications carriers in the prevalence of ASD were found.
Both deletion and duplication are associated with an increased risk of psychiatric disorder, supporting the importance
of early recognition, diagnosis, and intervention in these groups.
Introduction
Copy number variations (CNVs) in 16p11.2 (deletion
and duplication) between break points 4 and 5 (BP4–BP5)
(600 kb, chr16; 29.6–30.2 mb-HG19) occur at a frequency
of ~3 in 10,0001. Around 71% of the 16p11.2 deletions
occur de novo while the majority of the 16p11.2 dupli-
cations (70%) are familial2. This is consistent with the
notion that 16p11.2 deletions have a greater impact on
functioning, resulting in reduced fecundity3. Both 16p11.2
deletion and duplication have been associated with the
risk for autism spectrum disorder (ASD). Evidence comes
from studies of individuals with ASD4–11 with a meta-
analysis of 3613 cases reporting a prevalence of 0.50%
(95%CI: 0.31–0.82%) for the 16p11.2 deletion and of
0.25% (96%CI: 0.14–0.56%) for the duplication12. The
16p11.2 duplication, but not deletion, has been linked to
risk of schizophrenia in a meta-analysis of 16,772 cases
reporting a prevalence of 0.35% (95%CI: 0.27–0.45%) in
cases compared to 0.03% in controls (95%CI:
0.02–0.05%)13. This has been supported by comparisons
of schizophrenia patients and controls13 and
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parent–proband trios14. The effect of these CNVs on
mean IQ is a decrease of approximately two standard
deviations for the deletion and one standard deviation for
the duplication2,15,16. Apart from ASD, studies of 16p11.2
deletion carriers indicate high frequencies of attention
deﬁcit hyperactivity disorder (ADHD) (19%15 to 38%17),
anxiety disorders (6%15 to 25%18), mood disorders
(15%18), oppositional deﬁant disorder (ODD), and other
disruptive disorders (13%15 to 39%3). For carriers with the
duplication, high rates of ADHD (30%3) have been
reported.
Interestingly, these chromosomal rearrangements have
been associated with mirrored physical phenotypic effects.
The 16p11.2 deletion has been associated with the risk of
morbid obesity and large head circumference, while the
16p11.2 duplication has been associated with low body
mass index (BMI) and small head circumference2,18,19.
Taking into account evidence suggesting links between
small head circumference and schizophrenia20,21 and
large head circumference with autism22,23, it has been
suggested that these mirrored phenotypic effects (over-
growth versus undergrowth phenotype) extend to include
psychopathology24, although this has not yet been for-
mally evaluated. More speciﬁcally, it has been suggested
that differences in gene dosage associated with a single set
of genes within 16p11.2 (deletion) versus three copies
(duplication) may mediate risk of ASD versus schizo-
phrenia25,26. The 16p11.2 CNV has been presented as an
example of this theory, such that deletion carriers may be
at increased risk of ASD in particular, whilst duplication
carriers are at risk of ASD and schizophrenia2,18,26.
Despite strong evidence that 16p11.2 deletions and
duplications are associated with an increased risk of
psychiatric conditions, the majority of studies are based
on limited and non-systematic assessments (e.g., medical
records). Although informative, such records are less
suited to systematic evaluation of large samples, because
of differences between medical centers and clinicians in
diagnostic methods used and clinical documentation.
With the exception of schizophrenia and ASD, previous
studies have been based on relatively small samples,
without the availability of control samples to allow
comparisons.
Here, we report the largest study to date using detailed
systematically performed psychiatric assessments to
determine the nature and prevalence of psychopathology
in children with deletion or duplication of 16p11.2. We
hypothesized that children with 16p11.2 deletion and
duplication have a higher frequency of psychiatric dis-
order than family controls. We also hypothesized that
deletion carriers would be more severely affected than
duplication carriers, based on ﬁndings that the deletion is
more likely to arise de novo, whereas the duplication is
more frequently inherited. Finally, given the evidence that
the 16p11.2 CNV is associated with a mirror phenotype of
head and body size, we hypothesized that the children
with 16p11.2 deletion have a higher frequency of ASD
compared to those with 16p11.2 duplication while chil-
dren with 16p11.2 duplication have a higher frequency of
psychotic symptoms than those with 16p11.2 deletion.
Materials/subjects and methods
Sample
This study combined child samples (age <18 years old)
recruited through Medical Genetics clinics and collected
in Europe (EU) and the US (Table 1). The samples were
provided from the ECHO study, the 16p11.2 European
Consortium, the IMAGINE-ID study, and the Simons VIP
Consortium (Table 2). The sample characteristics of the
ECHO study, 16p11.2 European Consortium, and the
Simons VIP Consortium have been described else-
where2,15. The study methodology and sample assessment
of the UK ECHO study and IMAGINE-ID project are
identical. A subset of these families (i.e., from the Simon’s
VIP cohort) has been described in prior studies in terms
of their IQ, ASD, and schizophrenia diagnoses2,27.
Carrier status for the 16p11.2 deletion or duplication
was conﬁrmed for all individuals through clinical chro-
mosome microarrays, medical records and/or conﬁrma-
tion in a research laboratory. All participants had a CNV
Table 1 Description of 16p11.2 cohort, carrier groups,
and controls
Cohort by
carrier group
Sample
size
Male
(%)
Age,
mean (SD)
De novo
(%)
Inherited
16p11.2 deletion
European
Carriers 101 65 (64%) 9.5 (3.1) 45 (56%) 36 (44%)
Controls 22 16 (73%) 9.8 (3.1)
US
Carriers 116 61 (53%) 8.5 (3.3) 67 (74%) 23 (26%)
Controls 55 20 (36%) 9.8 (4.0)
16p11.2
duplication
European
Carriers 46 30 (65%) 9.0 (3.3) 9 (24%) 29 (76%)
Controls 7 5 (71%) 10.6 (5.7)
US
Carriers 68 35 (52%) 8.1 (3.7) 9 (16%) 46 (84%)
Controls 25 13 (52%) 8.1 (3.9)
Counts of de novo and inherited do not add up to 100% because a number of
carriers were of unknown status. Percentages are estimated not taking into
account individuals with unknown status
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in 16p11.2 BP4–BP5 region, excluding those in the adja-
cent region. Family members (siblings) who did not carry
the CNV participated as family controls (controls) (Table
1). To assess potential recruitment bias in children, as a
supplementary analysis, we further divided the carriers
into (a) probands (individuals who ﬁrst came to the
attention of medical services) and (b) relative carriers (i.e.,
their siblings who were identiﬁed and diagnosed following
CNV diagnosis of the proband) and compared the fre-
quencies of psychiatric diagnoses between these two
groups. Current analyses included individuals ≥3 years old
in order to standardize diagnoses, especially for ASD, in
very young children15.
The study was approved by the appropriate local ethics
committees and institutional review boards. Each parti-
cipant and his or her caregiver, when appropriate, pro-
vided informed written consent/assent to participate prior
to recruitment.
Psychiatric assessments
Assessments were performed using research diagnostic
instruments as previously reported2 under the supervision
of experienced and licensed clinicians who gave the best
estimate clinical and research DSM-IV-TR (Table 2).
Only diagnoses that were available for all participating
sites were examined. Only 2% of children with deletion
and duplication were diagnosed with any syndromal
psychotic disorder versus 0% of controls. Therefore, psy-
chotic symptoms were examined instead.
IQ scores have already been reported for this sample2.
We present the full-scale IQ scores and comparisons of
psychopathology for subgroups of carriers with and
without intellectual disability (ID, as deﬁned by IQ ≤ 70).
Statistical analysis
Data analysis was conducted using Stata (version 13)28.
Descriptive statistics were calculated to assess the fre-
quency of psychiatric disorder. Random effects logit
models were performed to determine whether group
status (e.g., probands versus controls) (independent vari-
able) was associated with an increased risk for psychiatric
disorder (dependent variable: 0= no diagnosis, 1= diag-
nosis present) while accounting for familial clustering (i.e.,
the family that each individual belongs to). Odds ratios
(ORs) and 95% conﬁdence intervals (95%CIs) were
derived and adjusted for age, sex, and cohort status (i.e.,
EU versus US)2. In cases where the maximum likelihood
estimates tended to inﬁnity (i.e., rare outcomes/zero
values), Firth’s method29 was used30. To assess recruit-
ment bias, we repeated these analyses comparing pro-
bands versus relative carriers. In order to reduce the
number of statistical comparisons, anxiety disorders were
included in the analyses as a summary variable (i.e., any
anxiety disorder). We tested the associations between
psychopathology and gender, inheritance status and ID
using the phi coefﬁcient.
Results
Table 1 shows the descriptive statistics of the sample by
cohort status (i.e., EU and US).
Deletion carriers versus family controls
217 carriers and 77 controls were included in the ana-
lyses. 48% of the carriers met criteria for at least one
psychiatric disorder (Table 3, S-Table 1, Fig. 1). This
prevalence was higher than for controls (17%, OR= 8.9, p
< 0.001). The most prevalent diagnosis in the carriers was
ADHD (29%). This prevalence was higher than in controls
(13%, OR= 4.0, p= 0.01). ASD was the second most
common diagnosis in carriers (22%), which was higher
than in controls (0%, OR= 39.9, p= 0.01). ID was also
more frequent among carriers (30%) than controls (0%,
OR= 58.7, p= 0.004). No signiﬁcant differences were
found in the prevalence of anxiety disorders, ODD/CD,
and psychotic symptoms in deletion carriers compared to
controls. Male children with deletions were more likely
Table 2 Measures used in the European and United States cohorts
Cohort Studies included Measures
European (EU) ECHO CAPA & ADI-R
IMAGINE-ID CAPA & ADI-R
16p11.2 European
Consortium
Clinical interviews & the Conners CBRS for children, ADI-R, and ADOS
United States (US) Simons VIP Consortium DISC and clinical observations for all subjects in combinations with IQ testing and supporting
measures (SCL-90, BAPQ, SRS), ADI-R, and ADOS
ECHO the Cardiff University ExperienCes of people witH cOpy number variants (ECHO) study (see http://medicine.cf.ac.uk/psychological-medicine-neuroscience/areas-
research/copy-number-variant-research/research-projects/), IMAGINE-ID intellectual disability and mental health: assessing genomic impact on neurodevelopment
(see http://www.imagine-id.org/), Simons VIP Consortium the Simons Variation in Individuals Project (VIP) Consortium (see https://www.simonsvipconnect.org/), CAPA
Child and Adolescent Psychiatric Assessment38, Conners CBRS Conners Comprehensive Behavior Rating Scales39, DISC Diagnostic Interview Schedule for Children40,
ADI-R the Autism Diagnostic Interview—Revised41, ADOS the Autism Diagnostic Observation Schedule41, SCL-90 Symptom Checklist—9042, BAPQ Broad Autism
Phenotype Questionnaire43, SRS Social Responsiveness Scale44
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than females to be diagnosed with any psychiatric dis-
order, ASD and ID, and individuals with inherited dele-
tion were more likely to have ID (S-Table 2).
Duplication carriers versus family controls
114 carriers and 32 controls were included in the ana-
lyses. 63% of the carriers had at least one psychiatric
disorder (Table 3, S-Table 1, Fig. 1). This frequency was
higher than for controls (31%, OR= 5.3, p= 0.01, Table
3). ADHD was the most common diagnosis in the carriers
(42%) and was elevated compared to controls (19%, OR=
7.0, p= 0.02). There were no differences in the prevalence
of anxiety disorders, ASD, ODD/CD, and psychotic
symptoms between carriers and controls. ID was higher in
carriers (34%) than controls (3%, OR= 56.7, p= 0.03).
Males were more likely to be diagnosed with ODD/CD,
and individuals with ID to be diagnosed with ASD (S-
Table 2).
Table 3 Psychiatric diagnoses, psychotic symptoms, and intellectual disability in children by 16p11.2 status
CHILDREN Deletion
Carriers (N= 217) Controls (N= 77) Odds ratio (95%CI) p
N (%) N (%)
Any diagnosis 105 (48) 13 (17) 8.9 (2.9–27.3) <0.001
Any anxiety disorder 20 (9) 2 (3) 3.0 (0.7–13.4) 0.16
ADHD 63 (29) 10 (13) 4.0 (1.3–11.9) 0.01
ASD 41 (22) 0 (0) 39.9 (2.4–660.5) 0.01
Psychotic symptoms 5 (4) 2 (4) 0.6 (0.1–2.7) 0.46
ODD/CD 15 (7) 0 (0) 9.3 (0.5–159.2) 0.12
IDa 61 (30) 0 (0) 58.7 (3.5–973.1) 0.004
Duplication
Carriers (Ν= 114) Controls (N= 32) Odds ratio (95%CI) p
N (%) N (%)
Any diagnosis 72 (63) 10 (31) 5.3 (1.6–17.1) 0.01
Any anxiety disorder 14 (12) 1 (3) 2.6 (0.3–23.6) 0.38
ADHD 48 (42) 6 (19) 7.0 (1.4–35.9) 0.02
ASD 26 (26) 3 (7) 4.5 (0.7–27.3) 0.10
Psychotic symptoms 7 (11) 0 (0) 2.2 (0.10–49.2) 0.61
ODD/CD 14 (12) 1 (3) 5.1 (0.6–46.0) 0.14
IDa 36 (34) 1 (3) 56.7 (1.5–2193.2) 0.03
Duplication versus deletion
Odds ratio (95%CI) p
Any diagnosis 2.8 (1.2–6.7) 0.02
Any anxiety disorder 2.0 (0.9–4.5) 0.09
ADHD 2.7 (1.0–7.1) 0.04
ASD 1.4 (0.6–3.0) 0.44
Psychotic symptoms 4.7 (1.3–17.8) 0.02
ODD/CD 2.1 (1.0–4.7) 0.06
IDa 1.8 (0.7–4.5) 0.19
Not all individuals had complete data on all diagnoses. Bold indicates p < 0.05. ID was not included in the overall rates of “any diagnosis”. The percentages represent
the proportion of individuals with available diagnoses
ADHD attention deﬁcit hyperactivity disorder, ASD autism spectrum disorder, ODD/CD oppositional deﬁant disorder/conduct disorder
aDeﬁned by IQ ≤ 70.
Niarchou et al. Translational Psychiatry             (2019) 9:8 Page 4 of 8
Deletion versus duplication carriers
Duplication carriers had higher frequencies of any diag-
nosis (OR= 2.8, p= 0.02), ADHD (OR= 2.7, p= 0.04) and
psychotic symptoms (OR= 4.7, p= 0.02) than deletion
carriers. No other differences were found (Table 3).
Assessment of potential recruitment bias
No differences were found between probands and
relative carriers with the deletion in the prevalence of
psychiatric disorders (S-Table 3). However, probands with
the duplication had higher frequencies of any psychiatric
disorder than relative carriers (OR= 3.9, p= 0.01).
Discussion
Psychiatric disorders in children with 16p11.2 deletion and
duplication
Our ﬁndings indicate that the mental health con-
sequences of the 16p11.2 deletion and duplication are
broad, similar to ﬁndings in other CNVs (e.g., 22q11.2
deletion syndrome31,32).
ASD frequencies were higher in deletion carriers when
compared to controls. In addition, almost half of the
carriers with either the deletion or duplication were
diagnosed with at least one psychiatric diagnosis, a fre-
quency much higher than for non-carriers. This is similar
to previously reported frequencies in medical records-
based studies of individuals with 16p11.2 deletion33 and
duplication3. ADHD was the most commonly diagnosed
disorder affecting between 30 and 40% of deletion and
duplication carriers, similar to the frequencies previously
reported3,15,17,18. ID was present in about a third of
deletion and duplication carriers and was also much more
common than amongst controls. The frequency of anxiety
and ODD/CD disorders and psychotic symptoms did not
differ between carriers and controls, consistent with the
previous studies15,18.
Previous studies in population-based samples of CNV
carriers have found high frequencies of cognitive
impairments and psychiatric symptoms24,34. This indi-
cates that these high frequencies are not attributable to
recruitment bias but are also representative of unselected
CNV populations. Indeed, we generally did not ﬁnd evi-
dence of ascertainment bias effects on phenotypic
assessment, as the frequencies of psychiatric diagnoses did
not differ between probands and relative carriers. The
only exception was our ﬁnding of higher frequencies of
any psychiatric diagnoses in child duplication compared
to relative carriers.
Although we found evidence for differences in the
prevalence of psychotic symptoms, we did not ﬁnd evi-
dence for differences in the prevalence of ASD between
16p11.2 deletion and duplication carriers, for which we
had more power. Thus, our ﬁndings do not provide
support of a mirror phenotype for a psychiatric disorder.
More generally, both deletion and duplication showed
signiﬁcant and overlapping psychopathology and any
differences were of degree rather than suggesting con-
trasting mirror effects at the level of psychopathology.
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Any diagnosis Any anxiety disorder ADHD ASD PS ODD/CD ID
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Fig. 1 Frequency of psychiatric diagnoses, psychotic symptoms, and intellectual disability in children with 16p11.2 deletion and
duplication. ADHD attention deﬁcit hyperactivity disorder, ASD autism spectrum disorder, ID intellectual disability, ODD/CD oppositional deﬁant
disorder/conduct disorder, PS psychotic symptoms
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Interestingly, we found associations between sex and
any psychiatric disorder, ASD and ID in children with
16p11.2 deletion and ODD/CD in children with 16p11.2
duplication, indicating an increased risk for males. No
other associations were found with ADHD or psychotic
symptoms which agrees with a previous study that
examined questionnaire responses18 as well as with ﬁnd-
ings related to another CNV on chromosome 22, resulting
in 22q11.2 deletion syndrome32. These ﬁndings point to
the possible negation of sex-related burden to some psy-
chiatric disorders by these CNVs35. Apart from an
increased risk of ASD in children with 16p11.2 duplica-
tion, psychiatric disorders did not occur more frequently
in participants with ID in children with 16p11.2 deletion
or duplication. Although this could reﬂect insufﬁcient
power, it could also indicate that these CNVs have
pleiotropic effects on IQ and psychopathology36. Finally,
there was an association between inherited status and
higher risk of ID indicating that potential parental genetic
and environmental effects might be negatively implicated
on child intelligence. There were no other associations
with inheritance status and psychiatric diagnoses, similar
to a previous study15.
Strengths and limitations
This is the largest study to date to perform detailed
phenotypic assessments on children with 16p11.2 deletion
and duplication and compare the frequency of psycho-
pathology with familial controls as well as between dele-
tion and duplication carriers.
Our ﬁndings may be inﬂuenced by ascertainment bias.
First, although we did not recruit individuals from
psychiatric services, ascertainment was based on a
phenotype signiﬁcant enough to trigger clinical genetic
testing (e.g., developmental delay). Second, although for
many phenotypes we did not ﬁnd evidence for recruit-
ment bias in our analyses, we did ﬁnd higher frequencies
of any psychiatric diagnoses in child duplication pro-
bands compared to child relative carriers. We have
previously explained our ascertainment strategies and
limitations15,32. It is noteworthy that there were rela-
tively high frequencies of psychopathology in familial
controls. 17% and 31% of non-carrier child relatives of
individuals with deletion and duplication, respectively,
met criteria for at least one psychiatric diagnosis. The
frequencies of ADHD (13% for deletion and 19% for
duplication) and ASD (7% for duplication) were higher
than we would expect from a population-based sample
(5–7% and 1%, respectively). Potential explanations
could be increased background environmental risk (e.g.,
the effect of family psychopathology), or perhaps the
presence of polygenic or other additional genetic back-
ground effects that could also be a result of assortative
mating. Irrespectively, our ﬁndings indicate that carriers
of deletion or duplication of CNV at 16p11.2 who come
to the attention of Medical Genetics services are at high
risk of psychiatric disorder, and this is of importance for
treating clinicians as well as the families themselves. If
anything, our estimates represent an underestimate,
given that the risks are elevated in our comparison
sample of non-carrying familial controls.
Finally, the assessments at all sites were made by
experienced clinicians and highly trained and clinically
supervised psychologists. However, there were differences
in the frequencies of psychiatric diagnoses and ID and
although we adjusted for cohort status, we cannot exclude
that potentially different diagnostic practices between the
sites and countries in this study might have played a role
in our ﬁndings. Further research is needed to examine
psychopathology associated with these CNVs in
population-based samples as well as to understand their
longitudinal course.
Clinical implications and future directions
This study clearly indicates that the phenotypic effects
of the 16p11.2 deletion and duplication extend to include
non-ASD psychopathology. The high frequency of psy-
chiatric disorders, especially ADHD, in childhood indi-
cates the need for recognition, diagnosis, and treatment
early in development. Longitudinal studies are needed to
examine the natural history of these disorders and whe-
ther speciﬁc types of treatment (e.g., stimulant medication
for ADHD) are beneﬁcial37. Not all children met criteria
for a psychiatric disorder, supporting previous literature
indicating that there is a spectrum of manifestations of the
16p11.2 deletions and duplications7, similar to other
CNVs (e.g., 22q11.2DS32).
Future studies could examine the extent to which
assortative mating plays a role in psychiatric risk in chil-
dren from families where a CNV is inherited compared to
where it occurs de novo. Further exploration of the extent
to which background genetic as well as environmental
risk factors contribute to the risk of psychiatric disorder in
carriers with a de novo versus an inherited CNV is also
important.
Conclusions
We examined the frequency of psychopathology in
children with 16p11.2 deletion and duplication. Our
ﬁndings indicate a high frequency of psychopathology
compared to familial controls and suggest the importance
of recognition, diagnosis, and intervention in early
development. The frequency of psychotic symptoms and
ASD is similar in deletion and duplication carriers, indi-
cating that mirrored physical effects of deletion and
duplication do not extend to psychopathology.
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